We are live on
!
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$268M
1-Year Est. Return
158.98%
This Fund
S&P 500
This Quarter
Est. Return
+39.3%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$77.2M
(+53%)
Cap. Flow
+$48M
Cap. Flow
% of AUM
21.55%
Top 10 Holdings %
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Molina Healthcare
MOH
|
+$8.43M |
| 2 |
Elevance Health
ELV
|
+$5.15M |
| 3 |
Intel
INTC
|
+$4.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$3.61M |
| 5 |
Johnson & Johnson
JNJ
|
+$3.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$4.82M |
| 2 |
UnitedHealth
UNH
|
+$3.15M |
| 3 |
iShares Bitcoin Trust
IBIT
|
+$2.87M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$2.84M |
| 5 |
Labcorp
LH
|
+$2.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.36% |
| 2 | Technology | 13.57% |
| 3 | Financials | 11.27% |
| 4 | Communication Services | 4.48% |
| 5 | Energy | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Exagen
XGN
$115M
| $80.4K | 0.04% |
+13,230
| New | +$120K |
|
277
iBio
IBIO
$67.1M
| $76.4K | 0.03% |
+39,585
| New | +$54K |
|
|
CNTB
278
Connect Biopharma Holdings
CNTB
$140M
| $75.5K | 0.03% |
+26,774
| New | +$57.1K |
|
279
Fulcrum Therapeutics
FULC
$243M
| $74.8K | 0.03% |
+6,615
| New | +$67.3K |
|
280
SAB Biotherapeutics
SABS
$268M
| $74K | 0.03% |
+19,790
| New | +$65.1K |
|
281
Spyre Therapeutics
SYRE
$8.65B
| $73.6K | 0.03% |
+2,246
| New | +$58.7K |
|
282
PUT
BridgeBio Pharma
BBIO
$15.9B
| $72K | 0.03% |
+536
| New | +$35.2K |
|
283
Aclaris Therapeutics
ACRS
$790M
| $67K | 0.03% |
+22,259
| New | +$56.2K |
|
284
CALL
Aquestive Therapeutics
AQST
$506M
| $65K | 0.03% |
+566
| New | +$3.53K |
|
|
285
PUT
Aquestive Therapeutics
AQST
$506M
| $59.4K | 0.03% |
+906
| New | +$5.65K |
|
286
PUT
CorMedix
CRMD
$628M
| $59.2K | 0.03% |
427
+198
| +86% | +$2.19K |
|
287
Protara Therapeutics
TARA
$231M
| $57.2K | 0.03% |
+10,733
| New | +$59.7K |
|
288
CALL
Vanda Pharmaceuticals
VNDA
$323M
| $57K | 0.03% |
+530
| New | +$2.92K |
|
|
AARD
289
Aardvark Therapeutics
AARD
$130M
| $55.5K | 0.02% |
+4,231
| New | +$52.8K |
|
290
PUT
Capricor Therapeutics
CAPR
$1.13B
| $55.5K | 0.02% |
+533
| New | +$6.96K |
|
291
Corbus Pharmaceuticals
CRBP
$166M
| $53.6K | 0.02% |
+6,587
| New | +$81.3K |
|
292
PUT
Viking Therapeutics
VKTX
$4.29B
| $52.5K | 0.02% |
+851
| New | +$30.2K |
|
|
NEUP
293
Neuphoria Therapeutics
NEUP
$18.4M
| $52K | 0.02% |
13,403
+8,495
| +173% | +$60.4K |
|
294
Pliant Therapeutics
PLRX
$67.5M
| $47.4K | 0.02% |
+38,831
| New | +$58.3K |
|
295
Codexis
CDXS
$201M
| $45.3K | 0.02% |
+27,813
| New | +$56.7K |
|
|
TECX
296
CALL
Tectonic Therapeutic
TECX
$619M
| $44.1K | 0.02% |
229
| – | – |
|
|
297
CALL
Regeneron Pharmaceuticals
REGN
$71.2B
| $43.9K | 0.02% |
+13
| New | +$8.83K |
|
298
Talphera
TLPH
$66.4M
| $41.8K | 0.02% |
+36,630
| New | +$44.2K |
|
|
YSG
299
Yatsen Holding
YSG
$334M
| $40.2K | 0.02% |
10,332
+5,332
| +107% | +$33.9K |
|
|
CMPS
300
Compass Pathways
CMPS
$1.58B
| $37.8K | 0.02% |
+5,483
| New | +$33.4K |
|
Similar funds
VC
AL
FC
NF
PF
UI
SSWM
AC
Persistent Asset Partners's Q4 2025 Portfolio in Review
As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Persistent Asset Partners deployed $48M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.
- Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
- Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
- Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
- Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
- Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
- Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
- Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.
Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.